139 related articles for article (PubMed ID: 12544176)
1. A prospective, open-label trial of olanzapine in adolescents with schizophrenia.
Findling RL; McNamara NK; Youngstrom EA; Branicky LA; Demeter CA; Schulz SC
J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):170-5. PubMed ID: 12544176
[TBL] [Abstract][Full Text] [Related]
2. Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.
Lindenmayer JP; Czobor P; Volavka J; Lieberman JA; Citrome L; Sheitman B; Chakos M; McEvoy JP
J Clin Psychiatry; 2002 Oct; 63(10):931-5. PubMed ID: 12416603
[TBL] [Abstract][Full Text] [Related]
3. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.
Labelle A; Bourget D; Boulay LJ; Ellis J; Tessier P
J Clin Psychopharmacol; 2002 Dec; 22(6):545-53. PubMed ID: 12454553
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
[TBL] [Abstract][Full Text] [Related]
5. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
6. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder.
Frazier JA; Biederman J; Tohen M; Feldman PD; Jacobs TG; Toma V; Rater MA; Tarazi RA; Kim GS; Garfield SB; Sohma M; Gonzalez-Heydrich J; Risser RC; Nowlin ZM
J Child Adolesc Psychopharmacol; 2001; 11(3):239-50. PubMed ID: 11642474
[TBL] [Abstract][Full Text] [Related]
7. Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
Dossenbach MR; Kratky P; Schneidman M; Grundy SL; Metcalfe S; Tollefson GD; Belmaker RH
J Clin Psychiatry; 2001; 62 Suppl 2():28-34. PubMed ID: 11232749
[TBL] [Abstract][Full Text] [Related]
8. Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents.
Kumra S; Jacobsen LK; Lenane M; Karp BI; Frazier JA; Smith AK; Bedwell J; Lee P; Malanga CJ; Hamburger S; Rapoport JL
J Am Acad Child Adolesc Psychiatry; 1998 Apr; 37(4):377-85. PubMed ID: 9549958
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study.
Dittmann RW; Meyer E; Freisleder FJ; Remschmidt H; Mehler-Wex C; Junghanss J; Hagenah U; Schulte-Markwort M; Poustka F; Schmidt MH; Schulz E; Mästele A; Wehmeier PM
J Child Adolesc Psychopharmacol; 2008 Feb; 18(1):54-69. PubMed ID: 18294089
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish Group for the Study of Olanzapine in Treatment-Refractory Schizophrenia.
Martín J; Gómez JC; García-Bernardo E; Cuesta M; Alvarez E; Gurpegui M
J Clin Psychiatry; 1997 Nov; 58(11):479-83. PubMed ID: 9413413
[TBL] [Abstract][Full Text] [Related]
11. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial.
Revicki DA; Genduso LA; Hamilton SH; Ganoczy D; Beasley CM
Qual Life Res; 1999 Aug; 8(5):417-26. PubMed ID: 10474283
[TBL] [Abstract][Full Text] [Related]
12. Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Godleski LS; Goldsmith LJ; Vieweg WV; Zettwoch NC; Stikovac DM; Lewis SJ
J Clin Psychiatry; 2003 Feb; 64(2):119-22. PubMed ID: 12633119
[TBL] [Abstract][Full Text] [Related]
13. Safety and effectiveness of olanzapine versus conventional antipsychotics in the acute treatment of first-episode schizophrenic inpatients.
Bobes J; Gibert J; Ciudad A; Alvarez E; Cañas F; Carrasco JL; Gascón J; Gómez JC; Gutiérrez M
Prog Neuropsychopharmacol Biol Psychiatry; 2003 May; 27(3):473-81. PubMed ID: 12691783
[TBL] [Abstract][Full Text] [Related]
14. Objective and subjective efficacy as well as tolerability of olanzapine in the acute treatment of 120 patients with schizophrenia spectrum disorders.
Lambert M; Holzbach R; Moritz S; Postel N; Krausz M; Naber D
Int Clin Psychopharmacol; 2003 Sep; 18(5):251-60. PubMed ID: 12920385
[TBL] [Abstract][Full Text] [Related]
15. Switching treatment-resistant patients with schizophrenia or schizoaffective disorder to olanzapine: a one-year open-label study with five-year follow-up.
Karagianis JL; LeDrew KK; Walker DJ
Curr Med Res Opin; 2003; 19(6):473-80. PubMed ID: 14594518
[TBL] [Abstract][Full Text] [Related]
16. Olanzapine in Chinese treatment-resistant patients with schizophrenia: an open-label, prospective trial.
Chiu NY; Yang YK; Chen PS; Chang CC; Lee IH; Lee JR
Psychiatry Clin Neurosci; 2003 Oct; 57(5):478-84. PubMed ID: 12950701
[TBL] [Abstract][Full Text] [Related]
17. Olanzapine versus haloperidol treatment in first-episode psychosis.
Sanger TM; Lieberman JA; Tohen M; Grundy S; Beasley C; Tollefson GD
Am J Psychiatry; 1999 Jan; 156(1):79-87. PubMed ID: 9892301
[TBL] [Abstract][Full Text] [Related]
18. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.
Bitter I; Dossenbach MR; Brook S; Feldman PD; Metcalfe S; Gagiano CA; Füredi J; Bartko G; Janka Z; Banki CM; Kovacs G; Breier A;
Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):173-80. PubMed ID: 14687871
[TBL] [Abstract][Full Text] [Related]
19. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
20. Outcome of Youth with Early-Phase Schizophrenia-Spectrum Disorders and Psychosis Not Otherwise Specified Treated with Second-Generation Antipsychotics: 12 Week Results from a Prospective, Naturalistic Cohort Study.
Vernal DL; Kapoor S; Al-Jadiri A; Sheridan EM; Borenstein Y; Mormando C; David L; Singh S; Seidman AJ; Carbon M; Gerstenberg M; Saito E; Kane JM; Steinhausen HC; Correll CU
J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):535-47. PubMed ID: 26375767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
